(Q36577367)

15 August 2017

1 reference

title

Cytokine networks--towards new therapies for rheumatoid arthritis (English)

1 reference

15 August 2017

1 reference

Iain B McInnes

1

0 references

Eddy Liew

series ordinal

2

object named as

Foo Y Liew

1 reference

15 August 2017

1 November 2005

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

1 reference

15 August 2017

1

1 reference

15 August 2017

31-39

1 reference

15 August 2017

1

1 reference

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Reverse signaling through membrane-bound interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

The balance of Th1/Th2 cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Interleukin-17 family members and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Reduced Incidence and Severity of Collagen-Induced Arthritis in Mice Lacking IL-18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Combined Effects of IL-12 and IL-18 on the Induction of Collagen-Induced Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Local interleukin-12 gene transfer promotes conversion of an acute arthritis to a chronic destructive arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Blocking IL-1 in systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Oncostatin M: foe or friend?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

New strategies to control inflammatory synovitis: interleukin 15 and beyond

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

A proinflammatory role for IL-18 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Adipocytokines in synovial fluid

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Resistin, an adipokine with potent proinflammatory properties

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0020

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0020

1 reference

15 August 2017

1 reference

PubMed ID

16932625